BACKGROUND: In @entity565 , persistent @entity32 might be the result of (1) an impaired ability to clear inflammatory cells from the airways and/or (2) impaired apoptotic responses. OBJECTIVE: In a @entity19 model, we investigated the regulatory role of Fas ( @entity1309 )-induced apoptosis in the development and resolution of airway @entity32 and @entity1224 ( @entity1224 ). METHODS: @entity19 that were either Fas-sufficient (wild-type; @entity7097 ) or @entity24344 (lpr ) were sensitized by intraperitoneal injections of ovalbumin (OVA) and challenged once intranasally with OVA ( @entity7173 @entity19 ). Control (IN) @entity19 were challenged only. RESULTS: @entity7173 @entity19 developed @entity1224 at 48 hours; changes in airway resistance resolved by 96 hours. Airway responsiveness at 48 hours in @entity7173 lpr @entity19 was similar to that in @entity7173 @entity19 . However, in contrast to @entity7097 @entity19 , @entity7173 lpr @entity19 sustained significant @entity1224 at 96 hours in comparison with IN lpr @entity19 ; the @entity1224 resolved by 6 days. Bronchoalveolar lavage fluid cell composition was similar in all of the different groups at 48 hours and 96 hours. Both @entity7173 @entity19 and lpr @entity19 exhibited similar tissue @entity1712 , whereas @entity7173 lpr @entity19 had significantly lower numbers of TdT-mediated @entity1977 nick end labeling (TUNEL)-positive cells in comparison with @entity7173 @entity19 at 48 hours. Anti- @entity59 antibody given to @entity7173 lpr @entity19 48 hours and 72 hours after the challenge significantly decreased @entity1224 and @entity32 and increased TUNEL-positive cell numbers at 96 hours. CONCLUSION: These results suggest that Fas expression can regulate the onset and resolution of @entity1224 through an increase in eosinophil apoptosis.

Fas deficiency delays the resolution of XXXX after allergen sensitization and challenge.

@entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia'] @entity32 :: ('MESH:D007249', 'Disease') :: ['eosinophilic inflammation', 'inflammation'] @entity59 :: ('16191(Tax:10090)', 'Gene') :: ['IL-5'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse', 'Mice'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity7097 :: ('MESH:C536751', 'Disease') :: ['WT'] @entity24344 :: ('MESH:C535950', 'Disease') :: ['Fas-deficient'] @entity1977 :: ('CHEBI:17625', 'Chemical') :: ['dUTP'] @entity7173 :: ('MESH:D007184', 'Disease') :: ['IP-IN WT', 'IP-IN'] @entity1309 :: ('14102(Tax:10090)', 'Gene') :: ['CD95'] @entity1224 :: ('MESH:D000402', 'Disease') :: ['AHR', 'airway hyperresponsiveness']
@entity1224 :: (MESH:D000402,Disease) :: ['airway hyperresponsiveness']
